Bayer HealthCare, a Germany Headquarter Chemical Company, is buying Teva Pharmaceuticals, a US-based animal health business, for USD 60 million up front, plus up to USD 85 million in manufacturing and sales milestones. Bayer HealthCare maintains taking on Teva’s the animal health operation will allow the expansion of its companion (pet food) and food animal product lines in the U.S., including the introduction of anti-infective and reproductive hormones. The Teva business will be integrated into Bayer’s own animal health business.
Featured News
The Hidden Security Risk Inside Your Company’s AI Tools
Mar 13, 2026 by
CPI
EU’s Largest Economies Push to Reduce Reliance on Foreign Payment Systems
Mar 12, 2026 by
CPI
Warren Presses Amazon for Answers on Pricing Practices for Government Buyers
Mar 12, 2026 by
CPI
EU Antitrust Chief Raises Concerns Over Big Tech Control of AI
Mar 12, 2026 by
CPI
Burson Adds Senior Advisor to Strengthen Competition Team
Mar 12, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece